Evolus, Inc. is a pioneering pharmaceutical company based in the United States, specializing in performance beauty products. With a strong focus on ESG factors, Evolus caters to the self-pay aesthetic market with its innovative product, Jeuveau. This proprietary botulinum toxin type A formulation is designed to temporarily improve the appearance of frown lines in adults. Evolus generates revenue from product sales in the US and Europe, as well as service revenue from distribution partners in Canada. With an ESG score of 40.1, the company is dedicated to sustainability and governance practices.